<DOC>
	<DOC>NCT01447082</DOC>
	<brief_summary>The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e. the comparison group) and to quantify the risk of developing newly diagnosed outcomes of interest in new users of quetiapine XR as well as in other study drugs.</brief_summary>
	<brief_title>General Practice Research Database Seroquel XR Safety Study</brief_title>
	<detailed_description>Epidemiology study to assess the safety of a new slow-release form of Seroquel (quetiapine) in the post-marketing phase in the UK.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Episodes of new use (&gt;/=1 prescription) of quetiapine XR or other study drugs Less than two years of recorded history before the start of the marketing of quetiapine XR (or cohort entry date) If the duration and dose of the antipsychotic drug cannot be determined</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>atypical</keyword>
	<keyword>antipsychotics</keyword>
	<keyword>quetiapine</keyword>
</DOC>